Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Forget Apple. It's time to collect from tax-dodging Gilead, tax group urges U.S. Treasury
Forget Apple. It's time to collect from tax-dodging Gilead, tax group urges U.S. Treasury
EU antitrust regulators this week cracked down on Apple, ordering the American tech giant to fork over about $14.
Betagenon AB: Start of Phase IIa Proof-of-Concept Clinical Trial of AMPK Activator O304 in Type 2 Diabetics
Betagenon AB: Start of Phase IIa Proof-of-Concept Clinical Trial of AMPK Activator O304 in Type 2 Diabetics
STOCKHOLM, Sweden I August 31, 2016 I Betagenon AB/Baltic Bio AB announces the start of Phase IIa proof-of-concept clinical trial of the first-in-class AMPK activator compound O304 in type2 diabetics.
Folic acid: what is it and should we all be taking it?
Folic acid: what is it and should we all be taking it?
Folic acid, aka folate or B9, is in the spotlight thanks to a new study which found food fortified with the B vitamin helped to lower rates of congenital heart defects in Canada.
Forensic DNA analysis checks the origin of cultured cells
Forensic DNA analysis checks the origin of cultured cells
Cell lines are cultured cells that are commonly used in medical research.
Mylan likely to 'get credit' for new EpiPen generic, but is it too little, too late?
Mylan likely to 'get credit' for new EpiPen generic, but is it too little, too late?
After a week scrabbling to calm the raging EpiPen pricing crisis, culminating with new copay assistance, Mylan on Monday unveiled its latest tactic.
AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries
AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries
REDWOOD CITY, CA, USA I August 29, 2016 I AcelRx Pharmaceuticals, Inc.
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results Of Tender Offer To Purchase All Of The Outstanding Shares Of Common Stock Of Sagent Pharmaceuticals, Inc.
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results Of Tender Offer To Purchase All Of The Outstanding Shares Of Common Stock Of Sagent Pharmaceuticals, Inc.
Nichi-Iko Pharmaceutical Co.
FDA: Test Blood Donations for Zika Virus
FDA: Test Blood Donations for Zika Virus
As a further safety measure against the emerging Zika virus outbreak, today the U.
Ecological consequences of amphetamine pollution in urban streams
Ecological consequences of amphetamine pollution in urban streams
Millbrook, NY -- Public Release.
New method of cancer immunotherapy developed
New method of cancer immunotherapy developed
SAN FRANCISCO, Aug.
Boosting brain protein alleviates Alzheimer's symptoms, study says
Boosting brain protein alleviates Alzheimer's symptoms, study says
LA JOLLA, Calif.
FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
 BOULDER, CO, USA -- August 23, 2016-- Clovis Oncology, Inc.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand